AIM ImmunoTech Highlights Ampligen’s Potential in Pancreatic Cancer; DURIPANC Results Expected in 2027
AIM ImmunoTech presented data suggesting Ampligen may enhance RAS-targeted therapy for pancreatic cancer. Phase 3 DURIPANC results are expected in 2027. Ampligen-treated patients showed 19.7 months median survival vs. 12.5 months for controls. RASolute 302 showed daraxonrasib's median survival of 13.2 months vs. 6.7 months with chemotherapy.
How this was made

The 30-second read
Why it matters
The filing provides the first public timeline for DURIPANC results, a material update for the company.
Market read
New trial timeline may influence AIM's valuation and peer comparisons.
What to watch
Potential partnership or licensing deals tied to the trial could add upside.
Background
AIM ImmunoTech highlighted Ampligen's role in pancreatic cancer and announced future Phase 3 readout dates.
Ticker impact
AIM ImmunoTech filed an 8‑K presenting that Phase 3 DURIPANC results are expected in Q1 2027.
likely downward pressure as investors price in later data
No new efficacy data released; only a future result date, which can reduce short‑term upside.
Market effects
May affect biotech peers tracking RAS‑targeted therapies.
Limited to US biotech investors.
Low; primarily relevant to niche oncology investors.
Counterpoint
The upcoming data could be a catalyst for a sharp rally if results exceed expectations.
Key entities
- companyAIM ImmunoTech Inc.
US‑listed biotech developing Ampligen for oncology.